Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine

2.50
Hdl Handle:
http://hdl.handle.net/2336/30434
Title:
Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine
Authors:
Jonsson, S; Vidarsson, G; Valdimarsson, H; Schiffman, G; Schneerson, R; Jonsdottir, I
Citation:
Eur. Respir. J. 2002, 20(4):813-8
Issue Date:
1-Oct-2002
Abstract:
This paper examines how pneumococcal type 6B polysaccharide conjugated to tetanus toxoid (Pn6B-TT) compares to a 23 valent pneumococcal vaccine (pneumococcal polysaccharide (PPS)-23) with respect to immunogenicity and serum opsonic activity in patients with chronic obstructive pulmonary disease (COPD). Patients with COPD aged 55-75 yrs were vaccinated with Pn6B-TT (n=10) or with PPS-23 (n=9). Healthy young adults (HA) were vaccinated with Pn6B-TT as controls. Total antibodies to serotype 6B polysaccharide were measured by radioimmunoassay and immunoglobulin (Ig)G antibodies by enzyme-linked immunosorbent assay. Opsonic activity was measured by a phagocytosis assay using human neutrophils as effector cells. The patient groups were comparable by age, smoking history, lung function and use of steroids. COPD patients vaccinated with Pn6B-TT or PPS-23 showed an increase in IgG antibodies and a nonsignificant increase in opsonic activity. This was similar to the increase in IgG and opsonic activity seen in HA. There was a significant correlation between antibody levels and opsonic activity in COPD patients vaccinated both with Pn6B-TT and PPS-23. Pneumococcal antibodies have been shown to confer protection from infection. The results of the present study indicate that protective immunity can be expected in elderly chronic obstructive pulmonary disease patients vaccinated with conjugate vaccines.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://erj.ersjournals.com/cgi/content/abstract/20/4/813

Full metadata record

DC FieldValue Language
dc.contributor.authorJonsson, S-
dc.contributor.authorVidarsson, G-
dc.contributor.authorValdimarsson, H-
dc.contributor.authorSchiffman, G-
dc.contributor.authorSchneerson, R-
dc.contributor.authorJonsdottir, I-
dc.date.accessioned2008-06-25T10:04:09Z-
dc.date.available2008-06-25T10:04:09Z-
dc.date.issued2002-10-01-
dc.date.submitted2008-06-25-
dc.identifier.citationEur. Respir. J. 2002, 20(4):813-8en
dc.identifier.issn0903-1936-
dc.identifier.pmid12412669-
dc.identifier.doi10.1183/09031936.02.00289702-
dc.identifier.urihttp://hdl.handle.net/2336/30434-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractThis paper examines how pneumococcal type 6B polysaccharide conjugated to tetanus toxoid (Pn6B-TT) compares to a 23 valent pneumococcal vaccine (pneumococcal polysaccharide (PPS)-23) with respect to immunogenicity and serum opsonic activity in patients with chronic obstructive pulmonary disease (COPD). Patients with COPD aged 55-75 yrs were vaccinated with Pn6B-TT (n=10) or with PPS-23 (n=9). Healthy young adults (HA) were vaccinated with Pn6B-TT as controls. Total antibodies to serotype 6B polysaccharide were measured by radioimmunoassay and immunoglobulin (Ig)G antibodies by enzyme-linked immunosorbent assay. Opsonic activity was measured by a phagocytosis assay using human neutrophils as effector cells. The patient groups were comparable by age, smoking history, lung function and use of steroids. COPD patients vaccinated with Pn6B-TT or PPS-23 showed an increase in IgG antibodies and a nonsignificant increase in opsonic activity. This was similar to the increase in IgG and opsonic activity seen in HA. There was a significant correlation between antibody levels and opsonic activity in COPD patients vaccinated both with Pn6B-TT and PPS-23. Pneumococcal antibodies have been shown to confer protection from infection. The results of the present study indicate that protective immunity can be expected in elderly chronic obstructive pulmonary disease patients vaccinated with conjugate vaccines.en
dc.language.isoenen
dc.publisherEuropean Respiratory Societyen
dc.relation.urlhttp://erj.ersjournals.com/cgi/content/abstract/20/4/813en
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshAntibodies, Bacterialen
dc.subject.meshCase-Control Studiesen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshIcelanden
dc.subject.meshImmunityen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshPneumococcal Vaccinesen
dc.subject.meshPneumonia, Pneumococcalen
dc.subject.meshProbabilityen
dc.subject.meshPulmonary Disease, Chronic Obstructiveen
dc.subject.meshSensitivity and Specificityen
dc.subject.meshStatistics, Nonparametricen
dc.subject.meshStreptococcus pneumoniaeen
dc.subject.meshVaccinationen
dc.subject.meshVaccines, Conjugateen
dc.titleVaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccineen
dc.typeArticleen
dc.identifier.eissn1399-3003-
dc.contributor.departmentDept of Immunology, Landspitali-University Hospital, Reykjavik, Iceland.en
dc.identifier.journalEuropean respiratory journal : official journal of the European Society for Clinical Respiratory Physiologyen

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.